The Global TB Caucus released a newsletter listing the key activities and outcomes of the Caucus for the first half of 2022.

The updated WHO consolidated guidelines on treatment of drug-susceptible TB include a new recommendation for the use of a 4-month regimen composed of isoniazid, rifapentine, moxifloxacin and pyrazinamid.

The University of Cape Town’s Lung Institute is conducting a new trial involving BTZ-043 (benzothiazinone DprE1 blocker), a novel TB drug candidate. There are also plans to test BTZ-043 in combination with two other new TB drug candidates. If all goes well, the new drug regimen could reduce TB treatment from the current six months to four.

Tuberculosis is a major public health concern, an ancient bacterial disease that has claimed the lives of kings, presidents, poets and at least one star of Hollywood's silver screen-era. Yet even now in the 21st century, it's still impossible to shake the scourge. TB kills someone around the globe every 22 seconds, the World Health Organization estimates.

The brochure provides a brief overview of up-to-date prevention, diagnosis, and treatment of TB based on human rights, high ethical standards, and a people-centered approach.

A report highlights stories from people living with HIV and TB in Ukraine to demonstrate the need for an ambitious pledge at the Global Fund's upcoming Seventh Replenishment in September 2022.

The 35th meeting of the Stop TB Partnership Board, held on 19-20 May 2022, called for an urgent enhancement of political commitment and funding to end TB by 2030, and for placing TB high on the political agenda ahead of 2023 UN High-Level Meeting on TB.

In their current form, South Africa’s TB preventive therapy (TPT) guidelines are out of step with the World Health Organization (WHO)’s guidance on TPT that recommends the use of new, shorter course TPT regimens, as well as providing TPT to all household contacts of people with TB.

Words Matter for people affected by TB: Call for everyone to champion empowering language free from stigma and discrimination.

In February, the CDC released provisional guidance for the use of pretomanid as part of the bedaquiline, pretomanid and linezolid (BPaL) regimen to treat drug-resistant tuberculosis.